Novo Nordisk A/S Seeks US And EU Approval for Degludec Insulin

BAGSVAERD, DENMARK--(Marketwire - September 26, 2011) -

Company Announcement no 60 2011: http://hugin.info/2013/R/1549968/477112.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1549968]


Media:
Katrine Sperling
Tel: (+45) 4442 6718
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact

Investors:
Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact

MORE ON THIS TOPIC